RxDoctor Payments Data

Daniel Silverman, MD

Nuclear Medicine · Los Angeles, CANPI 1295761880

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,960 of the $7,621 with a category attached, or 91.3%. Eisai Inc. accounts for 95.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $7,172 and has fallen 99.8% since, to $14 in 2025. Among nuclear medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,621in general payments, 2019–2025

Across 25 payments — averaging $304.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$7K
  • Novartis$316
  • Life Molecular Imaging Ltd$50
$140,887in research payments, 2019–2025

Across 134 payments — averaging $1051.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$141K

What the payments were for

  • Consulting fees$6,96091%
  • Food & beverage$6619%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.7$7,255
Novartis17$316
Life Molecular Imaging Ltd1$50

How this compares

$7,621 in reported general payments places this provider in the 90th percentile of 110 nuclear medicine providers in California.

See all nuclear medicine providers in California

Medicare billing

Part B allowed, 2024
$528,554
Medicare patients
1,209
Services billed
1,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →